On April 28, 2025, Quanterix Corporation and Akoya Biosciences announced an amendment to the terms of their previously announced merger agreement. Under the revised terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders.
Each Akoya share will now receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. This represents a reduction of over 9 million shares compared to the original deal terms, resulting in Quanterix shareholders owning approximately 84% of the combined company, up from 70%.
The amended merger agreement has been approved by both the Quanterix and Akoya Boards. Akoya shareholders holding more than 50% of Akoya’s common stock have agreed to vote in favor of the merger on the amended terms, and Quanterix will no longer hold its previously announced special meeting of shareholders. The transaction is expected to close during the second quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.